Eastern Virginia Medical School

Latest Eastern Virginia Medical School News

( BW)(NY-PALL)(PLL) Studies Validating Performance of Pall Prion Reduction Technology Presented at AABB Business Editors/Health/Medical Writers/Biotech Writers AABB Annual Meeting Booth #301 MULTIMEDIA AVAILABLE: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=4995553 EAST HILLS, N.Y.--(BUSINESS WIRE)--Oct. 17, 2005--Research studies demonstrating the effectiveness of prion filtration technology to safeguard the blood supply are being presented at the AABB Annual Meeting in Seattle, Washington, today. Prion diseases, such as variant Creutzfeldt-Jakob Disease (vCJD), the human form of Bovine Spongiform Encephalopathy or "mad cow" disease, are of growing concern to blood services worldwide because of the potential for transmission through transfusion from asymptomatic donors. Pall Corporation (NYSE: PLL) is presenting research results further validating the performance of its Leukotrap(R) Affinity Prion Reduction Filter System, which was CE marked with a 99.9 percent prion removal efficiency in May 2005. It is the first technology that reduces infectious prions from red cells, the most widely transfused blood component. A new study conducted by the American Red Cross and the Eastern Virginia Medical School, Norfolk Va., et.al., found that red blood cells filtered through the Leukotrap Affinity Prion Reduction Filter System retain their therapeutic value and quality after 42 days of storage. The samples tested showed mean values of 85.0 and 82.9 percent - more available